Simplified methods of assessing the impact of grid frequency dynamics upon generating plants

The frequency of the national electricity grid is affected by fluctuations in supply and demand, and so continually "judders" in an essentially unpredictable fashion around 50 Hz. At present such perturbations do not seemingly affect Nuclear Electric as most of their plant is run at more or less constant load, but they would like to be able to offer the national grid a mode of operation in which they "followed" the grid frequency: i.e., as the frequency rose above or fell below 50 Hz, the plant's output would be adjusted so as to tend to restore the frequency to 50 Hz. The aim is to maintain grid frequency within 0.2 Hz of its notional value. Such a mode of operation, however, would cause a certain amount of damage to plant components owing to the consequent continual changes in temperature and pressure within them. Nuclear Electric currently have complex computational models of how plants will behave under these conditions, which allows them to compute plant data (e.g., reactor temperatures) from given grid frequency data. One approach to damage assessment would require several years'-worth of real grid data to be fed into this model and the corresponding damage computed (via "cycle distributions" created by their damage experts). The results of this analysis would demonstrate one of three possibilities: the damage may be acceptable under all reasonable operating conditions; or it may be acceptable except in the case of an exceptional abrupt change in grid frequency (caused by power transmission line failure, or another power station suddenly going off-line, for instance), in which case some kind of backup supply (e.g., gas boilers) would be required; or it may simply be unacceptable. However, their current model runs in approximately real time, making it inappropriate for such a large amount of data: our problem was to suggest alternative approaches. Specifically, we were asked the following questions: - Can component damage be reliably estimated directly from cycle distributions of grid frequency? i.e., are there maps from frequency cycle distributions to plant parameter cycle distributions? - Can a simple model of plant dynamics be used to assess the potential for such maps? - What methods can be used to select representative samples of grid frequency behaviour? - What weightings should be applied to the selections? - Is it possible to construct a "cycle transform" (Fourier transform) which will capture the essential features of grid frequency and which can then be inverted to generate simulated frequency transients? We did not consider this last question, other than to say "probably not". We were supplied with data of the actual grid frequency measurements for the evening of 29/7/95, and the corresponding plant responses (obtained using Nuclear Electric's current computational model). A simplified nonlinear mathematical model of the plant was also provided. Two main approaches were considered: statistical prediction and analytical modelling via a reduction of the simplified plant model

Do the Barker Codes End?

A Barker code is a binary code with k^th autocorrelation <= 1 for all nonzero k. At the workshop, the Barker code group split into four non-disjoint subgroups: - An "algebra group", who explored symmetries of the search space that preserve the autocorrelations' magnitude. - A "computing group", who explored methods for quickly finding binary codes with very good autocorrelation properties. - A "statistics group", who explored ways to quantify what has been empirically observed about autocorrelation in the search space S_2^N. - A "continuous group", who explored a non-discrete analogue of the problem of finding sequences with good autocorrelations

Chronic wounds in Sierra Leone: searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital

BACKGROUND: Chronic wounds pose a significant healthcare burden in low- and middle-income countries. Buruli ulcer (BU), caused by Mycobacterium ulcerans infection, causes wounds with high morbidity and financial burden. Although highly endemic in West and Central Africa, the presence of BU in Sierra Leone is not well described. This study aimed to confirm or exclude BU in suspected cases of chronic wounds presenting to Masanga Hospital, Sierra Leone. METHODOLOGY: Demographics, baseline clinical data, and quality of life scores were collected from patients with wounds suspected to be BU. Wound tissue samples were acquired and transported to the Swiss Tropical and Public Health Institute, Switzerland, for analysis to detect Mycobacterium ulcerans using qPCR, microscopic smear examination, and histopathology, as per World Health Organization (WHO) recommendations. FINDINGS: Twenty-one participants with wounds suspected to be BU were enrolled over 4-weeks (Feb-March 2019). Participants were predominantly young working males (62% male, 38% female, mean 35yrs, 90% employed in an occupation or as a student) with large, single, ulcerating wounds (mean diameter 9.4cm, 86% single wound) exclusively of the lower limbs (60% foot, 40% lower leg) present for a mean 15 months. The majority reported frequent exposure to water outdoors (76%). Self-reports of over-the-counter antibiotic use prior to presentation was high (81%), as was history of trauma (38%) and surgical interventions prior to enrolment (48%). Regarding laboratory investigation, all samples were negative for BU by microscopy, histopathology, and qPCR. Histopathology analysis revealed heavy bacterial load in many of the samples. The study had excellent participant recruitment, however follow-up proved difficult. CONCLUSIONS: BU was not confirmed as a cause of chronic ulceration in our cohort of suspected cases, as judged by laboratory analysis according to WHO standards. This does not exclude the presence of BU in the region, and the definitive cause of these treatment-resistance chronic wounds is uncertain

Descriptive account of the first use of the LeVe CPAP System, a new frugal CPAP System, in adult patients with COVID-19 Pneumonitis in Uganda

Background Continuous positive airway pressure (CPAP) has been a key treatment modality for Coronavirus Disease 2019 (COVID-19) worldwide. Globally, the demand for CPAP outstripped the supply during the pandemic. The LeVe CPAP System was developed to provide respiratory support for treatment of COVID-19 and tailored for use in low- and middle-income country (LMIC) settings. Prior to formal trial approval, received in November 2021, these devices were used in extremis to support critically unwell adult patients requiring non-invasive ventilatory support. Methods This is a retrospective descriptive review of adult patients with COVID-19 pneumonitis, who were treated with advanced respiratory support (CPAP and/or high-flow nasal oxygen, HFNO) at Mengo Hospital, Uganda. Patients were treated with the LeVe CPAP System, Elisa CPAP and/or AIRVO™ HFNO. Treatment was escalated per standard local protocols for respiratory failure, and CPAP was the maximum respiratory support available. Data were collected on patient characteristics, length of time of treatment, clinical outcome, and any adverse events. Results Overall 333 patients were identified as COVID-19 positive, 44 received CPAP ± HFNO of which 43 were included in the study. The median age was 58 years (range 28–91 years) and 58% were female. The median duration of advanced respiratory support was 7 days (range 1–18 days). Overall (all device) mortality was 49% and this was similar between those started on the LeVe CPAP System and those started non-LeVe CPAP System devices (50% vs 47%). Conclusions The LeVe CPAP system was the most used CPAP device during the pandemic, bringing the hospital’s number of available HFNO/CPAP devices from two to 14. They were a critical resource for providing respiratory support to the sickest group of patients when no alternative devices were available. The devices appear to be safe and well-tolerated with no serious adverse events recorded. This study is unable to assess the efficacy of the LeVe CPAP System; therefore, formal comparative studies are required to inform further use

The lifetime of nitrogen oxides in an isoprene-dominated forest

The lifetime of nitrogen oxides (NOx) affects the concentration and distribution of NOx&nbsp;and the spatial patterns of nitrogen deposition. Despite its importance, the lifetime of NOx&nbsp;is poorly constrained in rural and remote continental regions. We use measurements from a site in central Alabama during the Southern Oxidant and Aerosol Study (SOAS) in summer 2013 to provide new insights into the chemistry of NOx&nbsp;and NOx&nbsp;reservoirs. We find that the lifetime of NOx&nbsp;during the daytime is controlled primarily by the production and loss of alkyl and multifunctional nitrates (&Sigma;ANs). During SOAS, &Sigma;AN production was rapid, averaging 90 ppt h-1 during the day, and occurred predominantly during isoprene oxidation. Analysis of the &Sigma;AN and HNO3 budgets indicate that &Sigma;ANs have an average lifetime of under 2 h, and that approximately 45 % of the &Sigma;ANs produced at this site are rapidly hydrolyzed to produce nitric acid. We find that &Sigma;AN hydrolysis is the largest source of HNO3&nbsp;and the primary pathway to permanent removal of NOx&nbsp;from the boundary layer in this location. Using these new constraints on the fate of &Sigma;ANs, we find that the NOx&nbsp;lifetime is 11&thinsp;&plusmn;&thinsp;5 h under typical midday conditions. The lifetime is extended by storage of NOx&nbsp;in temporary reservoirs, including acyl peroxy nitrates and &Sigma;ANs.</p

Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation

In this paper, we investigate the pharmacokinetics and effect of doxorubicin and cisplatin in vascularized tumors through two-dimensional simulations. We take into account especially vascular and morphological heterogeneity as well as cellular and lesion-level pharmacokinetic determinants like P-glycoprotein (Pgp) efflux and cell density. To do this we construct a multi-compartment PKPD model calibrated from published experimental data and simulate 2-h bolus administrations followed by 18-h drug washout. Our results show that lesion-scale drug and nutrient distribution may significantly impact therapeutic efficacy and should be considered as carefully as genetic determinants modulating, for example, the production of multidrug-resistance protein or topoisomerase II. We visualize and rigorously quantify distributions of nutrient, drug, and resulting cell inhibition. A main result is the existence of significant heterogeneity in all three, yielding poor inhibition in a large fraction of the lesion, and commensurately increased serum drug concentration necessary for an average 50% inhibition throughout the lesion (the IC50 concentration). For doxorubicin the effect of hypoxia and hypoglycemia (“nutrient effect”) is isolated and shown to further increase cell inhibition heterogeneity and double the IC50, both undesirable. We also show how the therapeutic effectiveness of doxorubicin penetration therapy depends upon other determinants affecting drug distribution, such as cellular efflux and density, offering some insight into the conditions under which otherwise promising therapies may fail and, more importantly, when they will succeed. Cisplatin is used as a contrast to doxorubicin since both published experimental data and our simulations indicate its lesion distribution is more uniform than that of doxorubicin. Because of this some of the complexity in predicting its therapeutic efficacy is mitigated. Using this advantage, we show results suggesting that in vitro monolayer assays using this drug may more accurately predict in vivo performance than for drugs like doxorubicin. The nonlinear interaction among various determinants representing cell and lesion phenotype as well as therapeutic strategies is a unifying theme of our results. Throughout it can be appreciated that macroscopic environmental conditions, notably drug and nutrient distributions, give rise to considerable variation in lesion response, hence clinical resistance. Moreover, the synergy or antagonism of combined therapeutic strategies depends heavily upon this environment

Complex needs in homelessness practice; a review of 'new markets of vulnerability'

This article reviews institutional responses to adult homeless people, to argue that there is a contemporary flourishing of debates about complex needs across homelessness research and practice fields. These understand housing need as a mental and physical health issue and a care and support need, with foundations in biographical and societal events, issues and experiences, including trauma. Responses to complex needs are conceptualised as enterprising in scope; articulated as fresh, proactive, preventative and positive. The article suggests that there are a range of legislative, policy and funding drivers for these developments, from across homelessness, housing support and adult social care fields, which are distinctive to the English context. At the same time, debates about what complex needs are, and how best to respond to them, are evident in international debates about service delivery models with homeless service users in the Global Western North. ‘Complex needs’ is defined as a travelling concept, with affective qualities, which provides foundation for practice interventions, techniques and principles in different locations. The article conceptualises institutional machinations around the governance of complex needs as ‘new markets of vulnerability’. This term theorises new markets and new marketising strategies around complex needs in the context of a much larger reconfiguring of the mixed economies of welfare around markets and market mimicking devices and practices. It is argued that the intensification of activities around complex needs give insight into processes of neoliberalisation in contemporary modernized welfare ‘mixes’